

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**TACROLIMUS EXTENDED-RELEASE CAPSULES OBTAIN DRUG
REGISTRATION APPROVAL**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Tacrolimus Extended-release Capsules (0.5mg, 1mg) (the “**Product**”) developed by the Group have obtained drug registration approval from the National Medical Products Administration of the People’s Republic of China and are deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Tacrolimus is a macrolide immunosuppressant and belongs to the class of calcineurin inhibitors. Both in vivo and in vitro studies have demonstrated that Tacrolimus has potent immunosuppressive effects and can inhibit the formation of cytotoxic lymphocytes responsible for graft rejection, with its mechanisms of action primarily including suppression of T-cell activation and T-helper cell-dependent B-cell proliferation, as well as inhibition of the formation of lymphokines (such as interleukin-2, interleukin-3 and γ -interferon) and the expression of interleukin-2 receptors. The Product is indicated for the prophylaxis of graft rejection after kidney transplantation, for the prophylaxis of graft rejection during the maintenance phase after liver transplantation, and for the treatment of graft rejection after kidney or liver transplantation that is refractory to other immunosuppressive agents.

The approval of the Product will further enrich the Group’s product portfolio in the therapeutic area of immunological rejection.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 13 October 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.